A microchip-based cell response assay system to an anticancer agent was developed. The hepatoma cell line HepG2 was used to assess the effects of an anticancer agent, doxorubicin. The required cell number was reduced by two orders, and the observation of the time course of cell response became possible. The system clearly showed that treatment with higher doses of the drug or longer exposure times gave more effects to cells. The possibilities of novel drug response studies or toxicity assay system were demonstrated.
Taking advantage of liquid microspace characteristics, we have demonstrated many microchip-based chemical systems, including flow-injection analysis, 3, 4 solvent extraction, [5] [6] [7] immunoassay, [8] [9] [10] organic synthesis, 11 and laser reaction control. 12, 13 Moreover, as one of the applications, a microchipbased cell culture system was developed. Functions of the hepatocytes could be maintained in this microchip. 14 This micro cell-culturing device provides some advantages, such as similar conditions in vivo and reduction in required amount of cells. Thanks to these advantages, a high performance cell-based bioassay system seems to be realized on a microchip. In this paper, we report on the development of a microchip-based cell response assay system to an anticancer agent.
Individual cancers, although they seem similar in types, show widely divergent responses to anticancer agents. Individual tumors may or may not respond to an agent used for a particular tumor type. Thus, a method that will predict the effects of the anticancer agents is needed before medication. Much research has been conducted on sensitivity testing for anticancer agents to treat cancers, employing such methods as the succinate dehydrogenase inhibition (SDI) test, 15 or histoculture drug response assay (HDRA). 16 These methods, however, require a relatively large number of cells. It is impractical to use these methods for a chemosensitivity test, because an operation would be necessary to obtain the required amount of cells. The aim of this study was development of a microbioassay system using a very small amount of cells to demonstrate the advantages of a microchip-based cell experiment system as a predictive drug response assay system. In the system, sensitivity to an anticancer agent, doxorubicin, of the cell line HepG2 was assayed as a model system.
Experimental
The cell cultures were carried out based on procedures described in a previous paper 14 with small modifications. Briefly, human hepatoma HepG2 cells were seeded in a microchannel (100 µm in depth and 250 µm in width) fabricated in a quartz glass microchip and incubated with medium flow system at 37˚C in a humidified atmosphere with 5% CO2 (Fig.  1) . When cells reached 60% confluence, they were dosed with varying concentrations (0 µM, 1 µM, 10 µM, 30 µM and 50 µM) of doxorubicin hydrochloride (Sigma) prepared in Doulbecco's modified Eagle's Medium (Gibco) supplemented with 10% Fatal Bovine Serum (Sigma) for periods of 0.5 h to 3 days. Doses of doxorubicin were chosen from blood levels of the drug just after administration (30 µM) and 1 h after administration (10 µM). Following the treatment, the viability of cells was examined using a mixture of 2 µM of Calcein-AM (Molecular Probes, λex = 495 nm, λem = 520 nm) and 4 µM of Ethidium homodimer (Molecular Probes, λex = 528 nm, λem = 617 nm) prepared in phosphate buffered saline (PBS) to indicate living cells and dead cells, respectively. This process was achieved by introduction of the reagent solution into the microchip by a microsyringe pump at ∼1 µL/min for 15 min, followed by taking fluorescent images using an Olympus CKX31. Cytosol of the living cell showed green fluorescence and nucleus of the dead cells showed red fluorescence.
Results and Discussion
Good cell growth was realized over the whole microchannel. By using the microchip with the cultured cells, a microchipbased bioassay system was developed. HepG2 cells were dosed with concentrations of doxorubicin ranging from 0 to 50 µM. Then, cell viability was examined with fluorescent dyes (Fig. 2) . Living cells and dead cells were counted. Obtained cell survival rates after 2 h, 24 h and 72 h of the treatment are shown in Fig. 3 . As can be seen clearly from the results, the anticancer agent produced both dose-dependent and time-dependent cell damage.
Our previous paper 14 showed that the activity and functions of the cells cultured in the microchip were retained fully. Therefore, the results were thought to be reliable. In addition, all of the operations were achieved by the control of the microsyringe pump, and then the assay operations became much easier and simpler than the conventional methods with many troublesome pipetting operations. Furthermore, the required cell number was reduced from 2.4 × 10 5 to 2.0 × 10 3 , which means that the assays under more than 100 dose conditions may become possible with cells sampled with needle biopsy. The system is practically useful because the damage to the patients is very little. Although the results obtained with the system are by no means conclusive, they do provide the early beginnings of an accurate drug response prediction test.
In this study, sensitivity of the target cells to the agent was assayed. This simple and rapid assay system will be very useful in drug screening process in drug development study and selection of appropriate drugs for a predictive therapy design. Moreover, the method can be applied to other assays, such as hepatotoxicity assay by using a primary culture of the patient's hepatocytes. In this application, the extremely low consumption of cells will become an obvious advantage. The system has a great potential to realize highly integrated and automated assays with high throughput. Detailed discussions will appear in a succeeding paper.
